Liposome-targeted delivery for highly potent drugs
Source abstract
Abstract
Considerable adverse side effects and cytotoxicity of highly potent drugs for healthy tissue require the development of novel drug delivery systems to improve pharmacokinetics and result in selective distribution of the loaded agent. The introduction of targeted liposomal formulations has provided potential solutions for improved drug delivery to cancer cells, penetrating delivery through blood-brain barrier and gene therapy. A large number of investigations have been developed over the past few decades to overcome pharmacokinetics and unfavorable side effects limitations. These improvements have enabled targeted liposome to meet criteria for successful and improved potent drug targeting. Promising in vitro and in vivo results for liposomal-directed delivery systems appear to be effective for vast variety of highly potent therapeutics. This review will focus on the past decade's potential use and study of highly potent drugs using targeted liposomes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran;
Biomedical Division, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, Iran;
Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran;
Medical Biomaterial Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran
References (100+)
Show source-provided references
1. 10.1016/j.jconrel.2014.10.01310.1016/j.jconrel.2014.10.013 ↗
2. 10.1208/s12248-009-9143-y10.1208/s12248-009-9143-y ↗
3. 10.1530/ERC-15-023710.1530/ERC-15-0237 ↗
4. 10.1021/bc100469710.1021/bc1004697 ↗
5. 10.1016/j.jconrel.2014.10.01810.1016/j.jconrel.2014.10.018 ↗
6. 10.1155/2011/32649710.1155/2011/326497 ↗
7. 10.1007/s11239-016-1440-610.1007/s11239-016-1440-6 ↗
8. 10.15171/ijb.139910.15171/ijb.1399 ↗
9. 10.1016/j.apsb.2013.12.00310.1016/j.apsb.2013.12.003 ↗
10. 10.1096/fj.12-21397510.1096/fj.12-213975 ↗
11. 10.1080/1061186080220113410.1080/10611860802201134 ↗
12. Cabanes A · Clin Cancer Res · 1999 · 5 · 687
13. 10.1002/anie.20090145210.1002/anie.200901452 ↗
14. 10.1371/journal.pone.008323910.1371/journal.pone.0083239 ↗
15. 10.1038/cgt.2010.1210.1038/cgt.2010.12 ↗
16. 10.1074/jbc.M110.12590610.1074/jbc.M110.125906 ↗
17. 10.1038/mt.2009.29110.1038/mt.2009.291 ↗
18. 10.1038/mt.2010.13610.1038/mt.2010.136 ↗
19. 10.1517/1742524090357996310.1517/17425240903579963 ↗
20. 10.5897/AJPPX2013.000410.5897/AJPPX2013.0004 ↗
21. 10.1208/aapsj07010410.1208/aapsj070104 ↗
22. 10.1016/j.expneurol.2003.12.01310.1016/j.expneurol.2003.12.013 ↗
23. 10.3109/21691401.2014.95363310.3109/21691401.2014.953633 ↗
24. 10.2217/nnm.13.11810.2217/nnm.13.118 ↗
25. 10.1016/j.copbio.2013.04.01410.1016/j.copbio.2013.04.014 ↗
26. Eliaz RE · Cancer Res · 2001 · 61 · 2592
27. 10.1016/j.colsurfb.2014.09.02910.1016/j.colsurfb.2014.09.029 ↗
28. 10.1016/j.bmcl.2016.01.07910.1016/j.bmcl.2016.01.079 ↗
29. 10.1073/pnas.84.21.741310.1073/pnas.84.21.7413 ↗
30. 10.1007/s00383-010-2703-510.1007/s00383-010-2703-5 ↗
31. 10.1016/j.addr.2004.01.01110.1016/j.addr.2004.01.011 ↗
32. 10.1016/S0005-2736(01)00432-110.1016/S0005-2736(01)00432-1 ↗
33. 10.1016/j.jconrel.2014.09.00110.1016/j.jconrel.2014.09.001 ↗
34. Gandhi R · Drug Deliv · 2015 · 23 · 115210.3109/10717544.2014.999960 ↗
35. 10.1166/jbn.2015.214510.1166/jbn.2015.2145 ↗
36. 10.1002/jctb.455510.1002/jctb.4555 ↗
37. Goren D · Clin Cancer Res · 2000 · 6 · 1949
38. 10.1016/j.jvs.2005.11.05710.1016/j.jvs.2005.11.057 ↗
39. 10.1016/j.jconrel.2004.03.00710.1016/j.jconrel.2004.03.007 ↗
40. 10.1016/j.addr.2015.10.02110.1016/j.addr.2015.10.021 ↗
41. He Y · Int J Nanomedicine · 2010 · 5 · 697
42. 10.1016/j.ijpharm.2010.02.03010.1016/j.ijpharm.2010.02.030 ↗
43. 10.1007/s11239-014-1071-810.1007/s11239-014-1071-8 ↗
44. 10.1146/annurev-bioeng-071910-12470910.1146/annurev-bioeng-071910-124709 ↗
45. 10.1007/978-1-4615-2938-5_510.1007/978-1-4615-2938-5_5 ↗
46. 10.1016/j.jconrel.2004.07.02310.1016/j.jconrel.2004.07.023 ↗
47. 10.1002/ijc.1024210.1002/ijc.10242 ↗
48. 10.1016/j.jconrel.2012.02.00410.1016/j.jconrel.2012.02.004 ↗
49. 10.1136/gutjnl-2011-30174610.1136/gutjnl-2011-301746 ↗
50. 10.1021/mp100380y10.1021/mp100380y ↗
51. 10.1080/1061186070145365310.1080/10611860701453653 ↗
52. 10.1016/j.jconrel.2013.01.00910.1016/j.jconrel.2013.01.009 ↗
53. 10.1016/j.biomaterials.2014.05.04010.1016/j.biomaterials.2014.05.040 ↗
54. 10.1081/DDC-12002587210.1081/DDC-120025872 ↗
55. 10.1211/002235701177552310.1211/0022357011775523 ↗
56. 10.1016/S0168-3659(02)00083-410.1016/S0168-3659(02)00083-4 ↗
57. 10.1038/nmat376510.1038/nmat3765 ↗
58. 10.1016/S0378-5173(01)00579-810.1016/S0378-5173(01)00579-8 ↗
59. 10.1007/BF0031126010.1007/BF00311260 ↗
60. 10.2147/IJN.S2918310.2147/IJN.S29183 ↗
61. Kontermann RE. · Curr Opin Mol Ther · 2006 · 8 · 39
62. 10.4161/cbt.13.1.1887110.4161/cbt.13.1.18871 ↗
63. 10.1016/j.ijpharm.2009.12.06110.1016/j.ijpharm.2009.12.061 ↗
64. 10.1016/j.jconrel.2009.05.03310.1016/j.jconrel.2009.05.033 ↗
65. 10.1016/j.biomaterials.2014.01.01910.1016/j.biomaterials.2014.01.019 ↗
66. 10.1016/j.biomaterials.2013.01.05510.1016/j.biomaterials.2013.01.055 ↗
67. 10.1016/j.ijpharm.2009.01.02310.1016/j.ijpharm.2009.01.023 ↗
68. 10.1021/mp100315q10.1021/mp100315q ↗
69. 10.1080/1061186X.2016.125856910.1080/1061186X.2016.1258569 ↗
70. Lopez-Berestein G, Fidler IJ. 1989. Liposomes in the Therapy of Infectious Diseases and Cancer. New York: Alan R. Liss, pp. 245–262.
71. 10.1208/aapsj08035510.1208/aapsj080355 ↗
72. 10.1016/j.ijpharm.2013.01.02510.1016/j.ijpharm.2013.01.025 ↗
73. 10.1016/j.biomaterials.2014.03.00710.1016/j.biomaterials.2014.03.007 ↗
74. 10.1098/rsta.2015.012910.1098/rsta.2015.0129 ↗
75. 10.4103/0971-6866.11287010.4103/0971-6866.112870 ↗
76. Mamot C · Cancer Res · 2003 · 63 · 3154
77. 10.1158/0008-5472.CAN-05-109310.1158/0008-5472.CAN-05-1093 ↗
78. 10.1016/S1470-2045(12)70476-X10.1016/S1470-2045(12)70476-X ↗
79. Martins S · Int J Nanomed · 2007 · 2 · 595
80. 10.1016/S0169-409X(96)00463-210.1016/S0169-409X(96)00463-2 ↗
81. 10.1016/j.addr.2010.09.00310.1016/j.addr.2010.09.003 ↗
82. 10.1074/jbc.M20042920010.1074/jbc.M200429200 ↗
83. Mathias CJ · J Nucl Med · 1996 · 37 · 1003
84. Medina OP · J Drug Deliv · 2011 · 2011 · 160515
85. 10.1021/bc900436510.1021/bc9004365 ↗
86. 10.2174/13892001279835693410.2174/138920012798356934 ↗
87. 10.2217/nnm.14.6210.2217/nnm.14.62 ↗
88. Moghimi HR · Iranian Journal of Pharmaceutical Research · 2016 · 15 · 3
89. 10.1038/455044a10.1038/455044a ↗
90. 10.1016/j.nano.2015.03.00610.1016/j.nano.2015.03.006 ↗
91. 10.15171/apb.2015.04310.15171/apb.2015.043 ↗
92. 10.4161/mabs.2.1.1078610.4161/mabs.2.1.10786 ↗
93. 10.1146/annurev.med.56.062904.14491510.1146/annurev.med.56.062904.144915 ↗
94. 10.1016/j.jconrel.2013.08.29810.1016/j.jconrel.2013.08.298 ↗
95. 10.1021/mp200439z10.1021/mp200439z ↗
96. 10.1038/nmat335510.1038/nmat3355 ↗
97. Park JW · Clin Cancer Res · 2002 · 8 · 1172
98. Pastorino F · Cancer Res · 2003 · 63 · 86
99. 10.1007/s11095-006-0022-210.1007/s11095-006-0022-2 ↗
100. 10.1016/j.drudis.2012.10.00210.1016/j.drudis.2012.10.002 ↗